Latest Commercial Strategy News

Page 6 of 22
BrainChip detailed significant progress in its neuromorphic AI technology and commercial strategy at its 2026 AGM, highlighting the AKD1500 chip launch and expanding defense and industrial collaborations.
Sophie Babbage
Sophie Babbage
6 May 2026
MC Mining has secured a US$90 million capital injection from Kinetic Development Group, which now holds a 51% controlling stake, accelerating the Makhado Project towards production. New board appointments signal a strategic shift as the company pivots from development to operational ramp-up.
Maxwell Dee
Maxwell Dee
5 May 2026
Nexsen Limited teams with Universiti Malaya to launch a joint research facility aiming to develop a rapid biosensor detecting E. coli and Salmonella simultaneously, addressing a critical food safety gap in Southeast Asia.
Ada Torres
Ada Torres
4 May 2026
Blue Star Helium has completed Stage 1 of its Galactica development, tying six wells into the Pinon Canyon facility and starting spot-priced helium sales. The company raised A$10 million to fund further project expansion and working capital.
Maxwell Dee
Maxwell Dee
30 Apr 2026
Alterity Therapeutics secures FDA backing on key Phase 3 elements for ATH434 in Multiple System Atrophy, bolstered by fresh Phase 2 data showing slowed disease progression and strategic leadership hires.
Ada Torres
Ada Torres
30 Apr 2026
Prairie Lithium has moved Pad #1 from groundwork to active building construction, backed by SaskPower's powerline installation and a binding Hydro Lithium offtake agreement that includes a A$10 million equipment contribution. First production is targeted for Q4 2026.
Maxwell Dee
Maxwell Dee
30 Apr 2026
Orthocell has initiated commercial sales of its Remplir nerve repair device in Canada, leveraging a distributor-led model to penetrate a US$75 million market and setting the stage for broader North American expansion.
Ada Torres
Ada Torres
30 Apr 2026
Racura Oncology reported robust progress in Q3 FY2026, including launching a key lung cancer trial and unveiling a novel blood test for cardioprotection, supported by a solid $19.38 million cash position.
Ada Torres
Ada Torres
30 Apr 2026
Optiscan Imaging has submitted its FDA dossier for InSpecta®, marking a crucial step toward US veterinary market entry, while progressing clinical studies for InVue® and InForm® ahead of further FDA submissions in 2026.
Ada Torres
Ada Torres
30 Apr 2026
Syntara Limited has raised A$10 million through a two-tranche placement and share purchase plan, backing its Phase 2b myelofibrosis trial and multiple clinical readouts following positive FDA feedback.
Ada Torres
Ada Torres
29 Apr 2026
PTR Minerals delivered standout assay results from its Rosewood Titanium Project, confirming extensive high-grade mineralisation and strong metallurgical performance, keeping its maiden JORC resource estimate on track for Q2 2026.
Maxwell Dee
Maxwell Dee
29 Apr 2026
Avecho Biotechnology has exceeded its Phase III CBD insomnia trial recruitment target by 16%, setting the stage for a more robust interim analysis scheduled for June 2026. The company’s commercial partnership with Sandoz AG and strengthened patent portfolio underpin its Australian market strategy.
Ada Torres
Ada Torres
29 Apr 2026

Browse the archive

Full archive